Today on Drug Discovery & Development
Salesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
As Peter Gassner, CEO of Veeva Systems, the influential cloud software provider for the life sciences industry, took the stage at the Veeva Commercial Summit in Boston, Salesforce announced that more than 140 life sciences organizations are using its competing Agentforce Life Sciences platform. In the mix as Salesforce clients are several marquee industry names…
Lilly’s retatrutide shows 28.3% weight loss, but increased side effects
Eli Lilly’s retatrutide, a triple hormone receptor agonist, has demonstrated an average weight loss of 28.3% over 80 weeks on the highest dose in Phase 3 trials. While this is more than the average weight loss of other GLP-1 drugs, the medicine comes with increased severity of side effects. Common side effects include nausea and…
Drug Discovery and Development See More >
Top pharma companies set sustainability goals, but emissions are still increasing
The health care industry contributes an estimated 4.4% of total global emissions annually. Approximately 71% of this comes from the health care supply chain, which includes the pharmaceutical and biotechnology sectors. Medicines contribute approximately 20% to 55% of health care’s total carbon footprint. This comes from corporate emissions, API production and manufacturing. Pharmaceutical manufacturing is…
SLAS 2026: Orchestration patforms, API-first instruments and the rise of semiautonomous labs
How digital tools and AI are accelerating drug discovery
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient
Sponsored Content See More >
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedSimplifying workflows is essential. Individuals in the pharmacy industry may accomplish more work with fewer errors by automating medication distribution.…
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
Genomics/Proteomics See More >
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
Infectious Disease See More >
FDA refuses to review Moderna’s mRNA flu vaccine
Moderna received a refusal-to-file (RTF) letter from the FDA’s Center for Biologics Evaluation and Research (CBER) for its investigational mRNA vaccine for influenza, the company said Tuesday. The letter is inconsistent with the feedback received at pre-Phase 3 and pre-submission consultations, Moderna said. The company has requested a meeting with the FDA. The vaccine, mRNA-1010,…
Oncology See More >
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
Biotech is heating up again. The SPDR S&P Biotech ETF (XBI) has gained roughly 69% over the past year. Global life sciences M&A hit $240 billion in 2025, an 81% jump from the prior year, with EY reporting a record $2.1 trillion in deal capacity. Goldman Sachs expects broader M&A volume to rise sharply in…
BioNTech made €19B in 2021. This quarter: €118M. Now it’s cutting 1,860 jobs and betting €16.8B in cash on returning to its oncology roots.
UCLA researchers advance EGFR-targeted drug for glioblastoma into clinical testing
Small study suggests probiotic yogurt strain may boost immunotherapy response in lung cancer
